financetom
Business
financetom
/
Business
/
Cash sweep scrutiny threatens wealth managers' credit ratings, Moody's says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Cash sweep scrutiny threatens wealth managers' credit ratings, Moody's says
Aug 16, 2024 5:17 AM

Aug 16 (Reuters) -

The spate of regulatory investigations into wealth managers' cash sweep

programs could hurt their credit ratings, Moody's warned on Thursday,

underscoring the threat to the high-margin business for firms like Morgan

Stanley ( MS ) and Wells Fargo ( WFC ).

WHY IT'S IMPORTANT

A potential ratings downgrade would increase the costs for wealth managers

at a time when worries about the economy are growing, with some forecasting a

downturn due to the tight monetary policy.

CONTEXT

Cash sweep programs allow wealth managers to move un-invested cash in

brokerage accounts to partner banks, enabling clients to earn returns on idle

funds.

However, these arrangements have led to disputes, as the interest paid

by partner banks is typically lower than what customers could earn through other

options, such as money market funds.

To prevent these conflicts, wealth managers have started giving clients

more choices. Customers can opt to park their un-invested money in tax-exempt

funds or other vehicles instead of moving it to their brokers' partner banks.

Morgan Stanley ( MS ), Wells Fargo ( WFC ) and Bank of America ( BAC ) have also raised the

interest rates they pay on some brokerage accounts.

Despite these efforts, regulatory investigations remain a concern. Wells

Fargo ( WFC ) and Morgan Stanley ( MS ) have disclosed their cash sweep programs are under

review from the SEC, while Bank of America ( BAC ) highlighted it as a potential risk

factor in its quarterly filing.

Moody's said that having multiple revenue streams will help mitigate

the risk for larger firms. However, private-equity owned wealth managers with

high debt burdens and less diversified business models are likely to be more

severely affected.

The investigations could squeeze margins across the industry by prompting

firms to increase the interest on brokerage accounts, the ratings agency added.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Brazil's Embraer sees deliveries, revenue growing in 2024
Brazil's Embraer sees deliveries, revenue growing in 2024
Mar 18, 2024
SAO PAULO (Reuters) - Brazilian planemaker Embraer ( ERJ ) expects both its aircraft deliveries and revenues to grow in 2024, the company said on Monday. The world's third-largest planemaker behind Boeing ( BA ) and Airbus estimated it will deliver between 125 and 135 executive jets this year, compared with 115 in 2023. Deliveries from its commercial aviation segment...
--Wedbush Trims ONE Group Hospitality's PT to $5 From $6, Says 2024 Visibility Remains Limited; Maintains Neutral Rating
--Wedbush Trims ONE Group Hospitality's PT to $5 From $6, Says 2024 Visibility Remains Limited; Maintains Neutral Rating
Mar 18, 2024
07:15 AM EDT, 03/18/2024 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us) ...
Romanian nuclear project has $4 bln in U.S. financial support, says ambassador
Romanian nuclear project has $4 bln in U.S. financial support, says ambassador
Mar 18, 2024
DOICESTI, Romania, March 18 (Reuters) - A small modular nuclear reactor project in Romania has financial support worth $4 billion from United States Exim Bank and the United States International Development Finance Corporation, U.S. Ambassador Kathleen Ann Kavalec said on Monday. ...
AstraZeneca to cap US out-of-pocket costs for inhalers at $35 per month
AstraZeneca to cap US out-of-pocket costs for inhalers at $35 per month
Mar 18, 2024
(Reuters) -AstraZeneca ( AZN ) said on Monday it would cap out-of-pocket costs for its inhaled respiratory products at $35 per month in the United States, starting June, following a similar move by rival Boehringer Ingelheim earlier this month. The cap would apply to all its respiratory products portfolio, including inhalers to treat asthma and chronic obstructive pulmonary disease (COPD),...
Copyright 2023-2026 - www.financetom.com All Rights Reserved